Prelude Therapeutics Stock Investor Sentiment
| PRLD Stock | USD 0.71 0.03 4.05% |
About 53% of Prelude Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Prelude Therapeutics suggests that many traders are impartial. The current market sentiment, together with Prelude Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prelude Therapeutics stock news signals to limit their universe of possible portfolio assets.
Prelude |
Prelude Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Prelude Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Prelude Therapeutics that are available to investors today. That information is available publicly through Prelude media outlets and privately through word of mouth or via Prelude internal channels. However, regardless of the origin, that massive amount of Prelude data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Prelude Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Prelude Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Prelude Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Prelude Therapeutics alpha.
Prelude Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Andrew Combs of 60000 shares of Prelude Therapeutics at 1.3667 subject to Rule 16b-3 | 12/23/2024 |
2 | Acquisition by Vaddi Krishna of 10000 shares of Prelude Therapeutics at 1.2 subject to Rule 16b-3 | 12/30/2024 |
3 | Acquisition by Vaddi Krishna of 5000 shares of Prelude Therapeutics at 1.2087 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Vaddi Krishna of 496000 shares of Prelude Therapeutics at 1.11 subject to Rule 16b-3 | 02/04/2025 |
5 | We Think Prelude Therapeutics Needs To Drive Business Growth Carefully | 03/04/2025 |
6 | Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 | 03/10/2025 |
7 | Acquisition by Vaddi Krishna of 47500 shares of Prelude Therapeutics at 0.7104 subject to Rule 16b-3 | 03/12/2025 |
8 | Acquisition by Vaddi Krishna of 50000 shares of Prelude Therapeutics at 0.7164 subject to Rule 16b-3 | 03/13/2025 |
9 | Acquisition by Vaddi Krishna of 29999 shares of Prelude Therapeutics at 0.7544 subject to Rule 16b-3 | 03/14/2025 |
10 | Insider Spends US70k Buying More Shares In Prelude Therapeutics | 03/19/2025 |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |